ADAnita Devlin

Anita Devlin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anita Devlin has a total of 217 co-authors. Here are the top co-authors by number of shared publications:

  • Alessio Masi

    Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, Florence, Italy

    2 shared publications
  • Annalaura Torella

    Department of Precision Medicine, University "Luigi Vanvitelli," Naples, Italy; Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy

    2 shared publications
  • Annalisa Vetro

    Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy

    2 shared publications
  • Atsushi Sugie

    Brain Research Institute, Niigata University, Niigata 951-8585, Japan

    2 shared publications
  • Celina von Stülpnagel

    Department of Pediatric Neurology and Developmental Medicine, Dr. v. Hauner Children's Hospital, LMU - University of Munich, München, Germany; Institute for Transition, Rehabilitation and Palliation, Paracelsus Medical University, Salzburg, Austria

    2 shared publications
  • Cristiana Pelorosso

    Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy

    2 shared publications

Latest Publications

  • Transdermal clonidine patch use in the management of childhood hypertonia: a cross-sectional UK-wide service evaluation

    by Daniel E Lumsden, Robert Spaull, Sarah Abernethy, Mayy El Gamal, Katharine Forrest, Louisa Akwaama Lemaire, Jean-Pierre Lin, Sofia Marques, Valerie Orr, Lucinda Carr, et al.

    Objectives Clonidine is increasingly used in the management of childhood motor disorders. Reports are limited regarding the use of transdermal clonidine patches (TCPs) for this indication. We aimed to explore the use of TCPs in children and young people (CAYP) across specialist movement disorder services in the UK. Methods A cross-sectional service evaluation of TCP use in CAYP with motor disorders was performed. Where available, historical data on TCP use were also collected. Results Data were available for 259 CAYP from 11 services, with 176/259 (68%) under active follow-up. Median age at starting TCPs was 8.6 years (25th to 75th centile 5.2–12 years). Gross Motor Function Classification System level (or equivalent) was V for 206/253 (81.4%) CAYP. Clinically significant chorea was observed in 33/255 (12.9%), spasticity in 116/254 (45.7%) and dystonia in 234/256 (91.4%) CAYP. The most common reasons for TCP initiation were overall dystonia severity (61/259, 23.6%), concerns about absorption of enteral medication (54/259, 20.8%) and excess sedation with enteral clonidine (46/259, 17.8%). TCP use had been discontinued by 61/259 (23.6%) CAYP, most commonly because of skin rash (24/259, 9.3%). The median time to discontinuing patches was 3.5 months. In addition to TCPs, 148/259 (57.1%) of CAYP continued with enteral clonidine. Additional tone-reducing medication use ranged from 0 to 6 additional medications (modal number of medications 3), Conclusion We present the first UK-based multicentre evaluation of TCP use in CAYP with motor disorders, highlighting the complexity of the medical problems of these CAYP and their clinical management. TCPs appear generally to be tolerated by CAYP, but further work is required to establish their efficacy.


  • Open Access

    Ketogenic diet therapy for epilepsy during pregnancy and lactation: An international survey exploring clinician perspectives

    by Kelly Faltersack, Tanya J. W. McDonald, Valentina De Giorgis, Bobbie Barron, Mackenzie C. Cervenka, Anita Devlin, Laura A. Healy, Magnhild Kverneland, Elles van der Louw, Mengyang Lu, et al.

    Objective: Ketogenic diet therapies (KDTs) are increasingly used as a treatment for people with epilepsy of childbearing potential (PWECP) and glucose transporter type 1 deficiency syndrome (Glut1DS). The aim of this study was to collect information on clinical experience with KDT during pregnancy and lactation in these populations. Methods: Between December 2023 and June 2024, an online survey was widely circulated to healthcare professionals (HCPs) working with PWECP and people with Glut1DS of childbearing potential on KDT. The survey explored KDT use during pregnancy and lactation. Only HCPs working with patients who expressed interest in KDT and who were planning to become pregnant or were already pregnant were invited to complete the survey. Results: Thirty‐five HCPs had counseled patients about whether to follow KDT during pregnancy. Sixty percent of HCPs did not recommend KDT during pregnancy. Key concerns included a lack of expertise with KDT use during pregnancy, insufficient data on the safety of KDT use during pregnancy, and uncertainty about the impact on fetal development. Among the HCPs (40%) who recommended KDT during pregnancy, there was no consensus regarding the version of KDT or optimal macronutrient composition. Even fewer HCPs ( n = 5) had provided counseling on diet adaptation during lactation. Low Glycemic Index Treatment and the modified Atkins diet were most recommended. Blood ketone monitoring was unanimously recommended during lactation. Significance: Based on the survey results, HCPs have variable opinions about the safety, management, ideal diet, and levels of ketosis for people with epilepsy (PWE) and Glut1DS on KDT during pregnancy and lactation. There was consensus about monitoring ketosis levels and ensuring micronutrient supplementation. Patient enrollment in pregnancy registries that capture KDT use is crucial to support future research and expand knowledge about the safety of KDT so HCPs and PWE or Glut1DS can make informed decisions about their treatment. Plain Language Summary: Most healthcare providers (HCPs) did not advise ketogenic diet therapy (KDT) for epilepsy during pregnancy, though some noted exceptions for glucose transporter type 1 deficiency syndrome. Their main concerns were not having enough information about safety for the parent and fetus and their own lack of experience using KDT during pregnancy. The 40% of HCPs who supported the use of KDT during pregnancy stressed the need for personalized care and close monitoring to reduce risks. Few HCPs have used KDT during lactation. Experts advised using more flexible versions of KDT during lactation. More research is needed.


  • Open Access

    An international survey on withdrawing the ketogenic diet therapy for epilepsy

    by Noémie Donnard, Sophie Höhn, Anita M Devlin, Eric H. Kossoff, Natasha E Schoeler, Elles van der Louw, Jong M. Rho, Blandine Dozières-Puyravel, Stéphane Auvin


  • Open Access

    Ketogenic diet registry for epilepsy: A cross-sectional feasibility study

    by Elizabeth G. Neal, Victoria J. Whiteley, Elles van der Louw, Anita M. Devlin, Christin Eltze, Suresh Pujar, Zoe Simpson, Isobel Hardy, Alison Palmer, Agnieszka Szmurlo, et al.


  • Open Access

    Efficacy and safety of ketogenic diet in infants with epilepsy: KIWE RCT

    by Natasha E Schoeler, Louise Marston, Laura Lyons, Sally Halsall, Ruchika Jain, Siobhan Titre-Johnson, Maryam Balogun, Simon J R Heales, Simon Eaton, Michael Orford, et al.

    Background: Many infancy-onset epilepsies have a poor prognosis for seizure control and neurodevelopmental outcome. Ketogenic diets can improve seizures in older children and adults unresponsive to antiseizure medicines. We aimed to determine the effectiveness of the ketogenic diet in reducing seizure frequency compared to further antiseizure medicine in infants with drug-resistant epilepsy. Methods: In this randomised, open-label trial, 136 infants with epilepsy, aged 1–24 months, with > 4 seizures/week and a previous trial of ≥ 2 antiseizure medicines were recruited from 19 hospitals in the United Kingdom. Following a 1- or 2-week observation period, participants were randomised to receive the classical ketogenic diet or a further antiseizure medicine for 8 weeks, using a computer-generated schedule without stratification. Treatment allocation was concealed from research nurses involved in patient care, but not from participants. The primary outcome was the number of seizures/day recorded during weeks 6–8. All analyses were intention to treat. The trial is registered with the European Union Drug Regulating Authorities Clinical Trials Database (2013-002195-40). Findings: Between 1 January 2015 and 30 September 2021, 136 eligible infants were randomised. Sixty-one (78%) of 78 assigned to a ketogenic diet and 47 (81%) of 58 assigned to antiseizure medicine had primary outcome data. At 8 weeks, the number of seizures per day, accounting for the baseline rate and randomised group, was not significantly different between groups [median (interquartile range) ketogenic diet 5 (1, 16); antiseizure medicine 3 (2, 11), incidence rate ratio 1.33, 95%, confidence internal 0.84 to 2.11; p = 0.22]. A similar number of infants reported at least one serious adverse event in both groups [antiseizure medicine: 24/56 (43%), ketogenic diet: 40/78 (51%)]. The most common serious adverse events were seizures in both groups. Three infants died during the course of the trial, all of whom were randomised to the ketogenic diet arm; deaths were considered to be unrelated to treatment. Interpretation: There was no evidence that a ketogenic diet was better than further antiseizure medicine in achieving seizure control in infants with epilepsy. The two treatments were similarly tolerated and a ketogenic diet appears safe to use in infants with epilepsy. A ketogenic diet could be a treatment option in infants whose seizures continue despite trial of two standard antiseizure medicines. Study registration: This study was registered as EudraCT 2013-002195-40. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 12/10/18) and is published in full in Efficacy and Mechanism Evaluation; Vol. 11, No. 16. See the NIHR Funding and Awards website for further award information.


  • Open Access

    Stretch-activated ion channel TMEM63B associates with developmental and epileptic encephalopathies and progressive neurodegeneration

    by Annalisa Vetro, Cristiana Pelorosso, Simona Balestrini, Alessio Masi, Sophie Hambleton, Emanuela Argilli, Valerio Conti, Simone Giubbolini, Rebekah Barrick, Gaber Bergant, et al.


  • Open Access

    Unjustified allegation on cancer risks in children of mothers with epilepsy taking high‐dose folic acid during pregnancy—No proof of a causal relationship

    by Randi von Wrede, Juri‐Alexander Witt, Stéphane Auvin, Anita Devlin, Lieven Lagae, Anthony Marson, Kimford J. Meador, Terence J. O'BRien, Jun Park, Rainer Surges, et al.


  • Open Access

    Stretch-activated ion channel TMEM63B associates with developmental and epileptic encephalopathies and progressive neurodegeneration

    by Annalisa Vetro, Simona Balestrini, Cristiana Pelorosso, Alessio Masi, Sophie Hambleton, Emanuela Argilli, Valerio Conti, Simone Giubbolini, Rebekah Barrick, Gaber Bergant, et al.

    By converting physical forces into electrical signals or triggering intracellular cascades, stretch-activated ion channels (SACs) allow the cell to respond to osmotic and mechanical stress. Knowledge of the pathophysiological mechanisms underlying associations of SACs with human disease is limited. Here we describe 16 unrelated patients, with severe early onset developmental and epileptic encephalopathy (DEE), intellectual disability, and severe motor and cortical visual impairment, associated with progressive neurodegenerative brain changes, carrying ten distinct de novo variants of TMEM63B , encoding for a highly conserved SAC. Variants were missense, including the recurrent V44M in 7/16 patients, or in-frame, and affected conserved residues located in transmembrane regions of the protein. In 12 patients, haematological abnormalities co-occurred, such as macrocytosis and haemolysis, requiring blood transfusions in some. We modelled V44M, R443H, and T481N in transfected Neuro2a cells and demonstrated leak inward cation currents across the mutated channel even in isotonic conditions, while the response to hypo-osmotic challenge was impaired, as were the Ca 2+ transients generated under hypo-osmotic stimulation. Ectopic expression of the V44M and G580C variants in Drosophila resulted in early death. TMEM63B -associated DEE represents a novel clinicopathological entity in which altered cation conductivity results in a severe neurological phenotype with progressive brain damage and early onset epilepsy, associated with haematological abnormalities in most patients.


  • Judith “Helen” Cross

    by Anita Devlin